先声药业2024年全年业绩报告显示，公司实现营收66.35亿元，同比仅增长0.4%，增速明显放缓。尽管如此，公司权益股东应占利润为7.33亿元，同比增长2.57%，经调整净利润达10.18亿元，同比增长41.6%。创新药收入占比提升至74.3%，贡献了49.28亿元的收入。神经科学和自身免疫领域收入分别增长10.4%和28%，但抗肿瘤领域收入下降17.6%。公司在2024年推出了两款新药，并有三项...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.